Stifel cuts Avalo Therapeutics stock price target on trial data
Covered in this story
Analyst targets on Avalo Therapeutics
- Oppenheimer: $6.93 → $16 by Oct 2027 · Outperform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AVTX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Avalo Therapeutics →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.